Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - 2017 Update
|出版商||La Merie Publishing||商品編碼||358307|
|出版日期||內容資訊||英文 58 Pages
|競爭企業分析:Avastin、Cyramza、Eylea、Lucentis的抗VEGF、抗VEGF-R生物相似藥及Bio-Superior Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - 2017 Update|
|出版日期: 2017年11月02日||內容資訊: 英文 58 Pages||
本報告提供以各種癌症的症狀、視網膜疾病的治療所採用的血管內皮層生長因子 (VEGF) 或其受體 (VEGF-R) 為標的之重組抗體的領域的競爭產品評價，各產品的銷售額、症狀的組合、開發平台，標的抗體、蛋白質的開發中現在進行中的計劃相關資訊等。
The Competitive Intelligence Report “Anti-VEGF & Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - a 2017 Update” provides a competitor evaluation in the field of recombinant antibodies, proteins and vaccines targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) for treatment of a variety of cancer indications and retinal diseases as of November 2017.
Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) are a highly successful class of products as evidenced by total sales of US$ 16 bln in 2016. Sales of anti-VEGF ophthalmic products continue to rise, while Avastin has come to an inflection point, also by the first approval of an Avastin biosimilar by the FDA.
The forthcoming patent expiries in the major markets have attracted a number of companies with global development of Avastin biosimilars in advanced clinical stages.
So far, less attention has been paid to anti-VEGF antibodies used for treatment of ophthalmic diseases although the approved antibody products are attractive targets for the second wave of biosimilar antibodies because of the impressive market growth fueled by the clinical success and patent expiries in the mid-term.
The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies, proteins or vaccines for treatment of cancer and neo-angiogenic eye diseases. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.